A Public Entity

Inland Empire Health Plan

PHARMACY TIMES

BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT

March 2, 2021

URGENT: Recalls, Market Withdrawals, & Safety Alerts

Dear IEHP Providers,

According to the FDA recall guidance, Title 21 Code of Federal Regulations Part 7 (21 CFR part 7), recalled products must be promptly removed or corrected. In an effort to promote health and wellness of our members, please review your records and notify members who may have been impacted by these recalls and market withdrawals.

Product Name	Product Code	Lot # and Exp. Date	Classification	Recalling Firm
Enoxaparin Sodium 100 mg/mL Injection	NDC: 60505-0795-01	CS008	MW	Apotex Corp
Enoxaparin Sodium 120 mg/mL Injection	NDC: 60505-0796-00	CT003	MW	Apotex Corp
Ketorolac Tromethamine 30 mg per mL Injection	NDC: 63323-0162-01; 63323-0162-00	6121083 Exp. 02/2021	Class I	Fresenius Kabi USA, LLC
Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL), 100 mL Single Dose Vial	NDC: 55150-0307-01	CAT200002, CAT200004, CAT200005, CAT200008, CAT200009 Exp. 09/2022; CAT200013, CAT200014, CAT200015, CAT200016, CAT200017, CAT200018 Exp. 10/2022	Class II	AuroMedics Pharma LLC
Nortriptyline HCl Capsules, equivalent to 10mg base	NDC: 51672-4001-01	AC05096, AC05098, C05099 Exp. 10/31/2022	Class II	Taro Pharmaceuticals U.S.A., Inc.
Metformin Hydrochloride 750 mg Extended-Release Tablets	NDC: 29033-0056-01	MET200601 Exp. 07/2022	Class II	Nostrum Laboratories Inc
Enoxaparin Sodium Injection, USP 100 mg/mL Single Dose Syringes with Automatic Safety Device For Subcutaneous Injection 10 x 1 mL Single Dose Syringes	NDC: 60505-0795-04; 60505-0795-01	CS008 Exp. 04/2022	Class I	Apotex Corp.

Enoxaparin Sodium Injection, USP 120 mg/ 0.8 mL Single Dose Syringes with Automatic Safety Device For Subcutaneous Injection 10 x 0.8 mL Single Dose Syringes	NDC: 60505-0796-04; 60505-0796-00	CT003 Exp. 05/2022	Class I	Apotex Corp.
Lidocaine/Tetracaine (LIPO110)* 23%/7% Ointment 100 GMS per 4 ounce plastic ointment jar	NDC Not Provided	95789 Exp. 04/17/2021	Class II	Stanley Specialty Pharmacy Compounding and Wellness Center
Cephalexin 250 mg per 5 mL for Oral Suspension, 100 ml (when mixed)	NDC: 67877-0545-88	19144841 Exp. 09/2021; 20141673 Exp. 04/2022.	Class II	Ascend Laboratories LLC
Cephalexin 250 mg per 5 mL for Oral Suspension, 200 ml (when mixed)	NDC: 67877-0545-68	19141869, 19141870 Exp. 03/2021; 19142762 Exp. 05/2021; 19143826, 19143923, 19143941, 19143954 Exp 07/2021	Class II	Ascend Laboratories LLC
Meclizine HCl 12.5 mg Tablets	NDC: 52536-0129-01	18030318 Exp. 03/2021	Class II	Wilshire Pharmaceuticals Inc
Meclizine HCl 25 mg Tablets	NDC: 52536-0133-01	18030329, 18030330, 18030331 Exp. 03/2021.	Class II	Wilshire Pharmaceuticals Inc

I = Class I Recall, II = Class II Recall, MW = Market Withdrawal

Additional information can be found at:

1. FDA Recalls, Market Withdrawals, & Safety Alerts: https://www.fda.gov/Safety/Recalls/default.htm
2. FDA Enforcement Report: http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm
3. IEHP Safety Resources: https://ww3.iehp.org/en/providers/pharmaceutical-services/clinical-information/safety-resources/

If you have any questions or comments regarding this recall, please call IEHP Pharmaceutical Services Department at 909-890-2049, 8am – 5pm (PST), Monday through Friday.

Sincerely,

IEHP Pharmaceutical Services